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bjectives In this study, we hypothesized that an antihuman-CD34 antibody immobilized on the
urface of commercially available sirolimus-eluting stents (SES) could enhance re-endothelialization
ompared with SES alone.
ackground Previous experience with antihuman-CD34 antibody surface modiﬁed Genous stents
GS) (OrbusNeich Medical, Fort Lauderdale, Florida) has shown enhanced stent endothelialization
n vivo.
ethods In the phase 1 study, stents were deployed in 21 pig coronary arteries for single stenting
9 vessels: 3 GS, 3 SES, and 3 bare-metal stents) and overlapping stenting with various combinations
12 vessels: 4 GSGS, 4 SESSES, and 4 GSSES) and harvested at 14 days for scanning electron
nd confocal microscopy. In phase 2, immobilized anti-CD34 antibody coating was applied on com-
ercially available SES (SES–anti-CD34, n  7) and compared with GS (n  8) and SES (n  7) and
xamined at 3 and 14 days by scanning electron/confocal microscopy analysis.
esults In phase 1, single stent implantation showed greatest endothelialization in GS (99%) and in
are-metal stent (99%) compared with SES (55%, p  0.048). In overlapping stents, endothelializa-
ion at the overlapping zone was signiﬁcantly greater in GSGS (95  6%) and GSSES (79  5%)
ompared with the SESSES (36  14%) group (p  0.007). In phase 2, SES–anti-CD34 resulted in
ncreased endothelialization compared with SES alone at 3 days (SES–anti-CD34 36  26%; SES
 3%; and GS 76  8%; p  0.01), and 14 days (SES–anti-CD34 82  8%; SES 53  20%; and
S 98  2%; p  0.009).
onclusions Immobilization of anti-CD34 antibody on SES enhances endothelialization and may
otentially be an effective therapeutic alternative to improve currently available drug-eluting
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69e-endothelialization after vascular injury results either
rom local recruitment of adjacent endothelial cells (ECs)
1) or from adhesion of blood-derived endothelial progen-
tor cells (EPCs) that differentiate and populate the surface
f the stent (2). Although the predominant mechanism of
tent endothelialization is still unclear, the biological process
f vascular healing after bare-metal stent implantation is
nown to be predictable and injury-dependent (3). In the
etting of drug elution, however, the pattern of vascular
See page 76
ealing is altered as there is a dynamic interaction between
he prolonged inhibitory effect caused by the drug on
mooth muscle and EC proliferation (4,5). Therefore, a
ajor challenge in the development of any drug-eluting
tent platform is to maintain sustained inhibition of smooth
ell proliferation while promoting EC coverage.
Previous experience with stents having immobilized an-
ihuman CD34 antibody on the device surface (Genous
io-engineered R stent, OrbusNeich, Fort Lauderdale,
lorida) has shown enhancing stent endothelialization in
itro (6) as well as feasibility and safety in the clinical setting
7,8). In this study, we tested the hypothesis that antihuman
D34 antibody immobilized on the surface of a commer-
ially available sirolimus drug-eluting stent (SES) would
nhance the degree of stent endothelialization compared
ith the SES surface alone. Using the healthy coronary
orcine model, we evaluated the differences in surface
ndothelialization between bare-metal stents (BMS), anti-
D34 antibody stents (Genous stent [GS]), and SES in
ingle and overlapping stents. Also, stent endothelialization
atterns were compared between commercially available
evices (SES and GS) and investigational SES with immo-
ilized anti-CD34 antibody (SES–anti-CD34).
ethods
n vitro EC studies. One biological effect of sirolimus on EC
unction was evaluated by measuring the degree of proliferation
f human coronary artery endothelial cells (HCAECs) and
PCs at different concentrations of the drug using a 3-(4,5-
imethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide cell
roliferation assay (9). HCAECs were seeded in a 24-well
late at a density of 10 to 20,000 cells/well and grown for
2 h in the presence of different concentrations of sirolimus
anging from 0 to 1 mmol/l. Dilutions of sirolimus were
repared in endothelial growth media-2 microvascular 
0% fetal bovine serum at the following final concentrations
0 nmol/l, 1 nmol/l, 10 nmol/l, 100 nmol/l, 1 m, 10 m,
00 m, 1 mmol/l); 50 l of each dilution were added to
riplicate wells of a 96-well tissue culture-treated plate and
he 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
romide assay was performed. Each assay was repeated at (east 3 times. For the EPC proliferation study, CD34 cells
ere immunomagnetically separated from human periph-
ral blood mononuclear cells. Selected CD34 cells were
hen expanded for 7 days in Stemline II Hematopoietic
tem Cell Expansion Medium (Sigma-Aldrich, St. Louis,
issouri) with StemSpan CC110-Cytokine Cocktail (Stem
ell Technologies, Vancouver, British Columbia, Canada)
nd G-CSF (Sigma-Aldrich). Cell phenotype was further
onfirmed by staining with anti-CD34 antibody before use
n cell studies. EPC were seeded in a 24-well plate with
bronectin-coated wells, at a density of 10 to 20,000
ells/well and were grown for 5days in the presence of 0 to
mmol/l of sirolimus after the same procedure used for the
CAEC incubation.
evice description. The technical features of the GS have
een previously published (8). In brief, the GS consist of a
16-l stainless steel R stent (R
tent) and Evolution 2 balloon
elivery catheter (OrbusNeich
edical, Inc.), with a surface
odification consisting of poly-
accharide base matrix and co-
alently bound anti-CD34 anti-
ody. The anti-CD34 antibody
s an IgG2a antibody directed
oward the class III epitope of
he CD34 membrane protein
xpressed on progenitor cells. A
lass III anti-CD34 isoform was
elected based on its cross-
eactivity with porcine species,
igh binding affinity for CD34,
nd its resistance to enzymatic
egradation. The amount of
nti-CD34 antibody attached to
he surface is 1 g/cm2 (1 g/13
m stent and 1.1 g/15 mm
tent) (Brian Hatcher, unpub-
ished data, 2006). The distribution of the coating has
een shown to be uniform when evaluated by fluorescence
icroscope and scanning electron microscope (SEM)
ith the use of a secondary fluorescein isothiocyanate- or
mmunogold-labeled antibody (antimurine antibody).
evices used in these studies included commercially avail-
ble 2.75, 3.0, and 3.5  13 and 15 mm SES (Cypher,
ordis Corp., Miami Lakes, Florida), GS (Genous Bio-
ngineered R Stent, OrbusNeich), and BMS (BX Sonic
tent, Cordis Corp.). The investigational SES–anti-CD34
tents were prepared by partial inflation of the sterile SES to
emove them from stent delivery catheter. The removed
ES were treated with the same anti-CD34 antibody
mmobilization process used for the GS. The modified
tents were crimped on Evolution 2 stent delivery catheters
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CM  confocal microscopy
EC  endothelial cell
EPC  endothelial progenitor
cell
GS  Genous stent(s)
HCAEC  human coronary
artery endothelial cell
PECAM  platelet
endothelial cell adhesion
molecule
SEM  scanning electron
microscope
SES  sirolimus-eluting
stent(s)
SES–anti-CD34  sirolimus-
eluting stents with
immobilized anti-CD34
antibodyOrbusNeich) and sterilized with gamma irradiation. To
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70onfirm that the drug content remained within the accep-
ance criteria (10% of reported nominal) for the SES,
ES–anti-CD34 stents were characterized before and after
amma sterilization by extraction in 100% methanol and
igh pressure liquid chromatography analysis. The total
rug content was within 10% of the reported nominal drug
ontent (8.5 g/mm), which is comparable to the original
ES. In addition, antibody activity, determined by binding
f CD34 cells, of test devices was comparable to control
S devices.
xperimental design. The study protocol was reviewed and
pproved by the Institutional Animal Care and Research
ommittee, Jack H. Skirball Center for Cardiovascular Re-
earch (Orangeburg, New York). All animals received humane
are in compliance with the Animal Welfare Act and the
Principles of Laboratory Animal Care” formulated by the
nstitute of Laboratory Animal Resources (National Research
ouncil, NIH Publication No. 85-23, revised 1996).
HASE 1 STUDY. Stents were randomized and deployed in
ormal coronary arteries in 7 pigs (21 coronary arteries) and
arvested at 14 days (Fig. 1). All 7 pigs were sacrificed at
ay 14 and analyzed for endothelialization using SEM and
onfocal microscopy (CM). Of 21 vessels examined at 14
ays, 9 single (3 GS, 3 SES, 3 BMS) and 12 overlapping stents
4 GSGS, 4 GSSES, 4 SESSES) were deployed in the
oronary arteries and analyzed by SEM and CM. For
mmuno-fluorescent staining followed by CM analysis, stented
egments were stained for platelet endothelial cell adhesion
olecule (PECAM)-1. The deployment technique involved
mplanting the distal stent first followed by the proximal
tenting, achieving an overlapping area of20% to 30% of the
ength of the stent (i.e., 5 mm). Therefore, the distal stent
as the “predominant surface” in contact with the vessel wall in
he overlapping zone.
HASE 2 STUDY. The biological effect of the anti-CD34
ntibody applied on the surface of SES was tested in a
eparate study (Fig. 1). In this study, a total of 22 single
tents were implanted in 13 pigs. Seven pigs were sacrificed
t 3 days (12 stents; 4 GS, 4 SES, 4 SES–anti-CD34) and
pigs at 14 days (10 stents; 4 GS, 3 SES, 3 SES–anti-
D34). All stents were assessed by SEM (visual estimation
or endothelialization) and CM (PECAM-1 expression).
tent implantation procedure. A total of 20 juvenile pigs
40 to 50 kg) were included. All animals were pre-treated
ith a daily dose of 325 mg aspirin and 75 mg clopidogrel
or 3 days before stent implantation. Sedation was achieved
ith a combination of ketamine (25 mg/kg), xylazine (2
g/kg), and acepromazine (0.2 mg) by intramuscular injec-
ion. An intravenous line was established, and the animals
ere intubated and ventilated with oxygen (2 l/min) and
soflurane 1.5% to 3.0% (2 l/min) using a respirator. Surgical
ccess was obtained via femoral artery. Before catheteriza-
ion, heparin (5,000 to 10,000 U) was administered to
aintain an activated clotting time of 250 to 300 s. aitroglycerin was administered intra-arterially to prevent or
elieve vasospasm. A vascular introducer sheath of appro-
riate size was placed in the access artery for advancement of
ngioplasty guiding catheters. Vascular devices were im-
lanted based on angiographic analysis of the vessel size.
fter allocation of the vessel to an experimental group, the
ppropriate stent was delivered to the intended site over a
uidewire using fluoroscopic guidance, and stent deploy-
ent was performed using a 1.1:1 stent-to-artery ratio. In
he overlap study, a second stent was implanted proximal to
he first stent with an overlap zone of approximately 5 to 6
m. After the procedure, the catheters were removed, the
rtery ligated, and the surgical incision repaired. Animals
ere recovered and housed until their designated day of
uthanasia (3 or 14 days).
istological analysis. Immediately after the surgical proce-
ure on the scheduled sacrifice day, the animals were
uthanized under general anesthesia by intravenous injec-
ion of pentobarbital euthanasia solution (100 mg/kg).
earts were excised and pressure-perfused with 0.9% saline
ntil cleared of blood, followed by pressure-perfusion fixa-
ion with 10% neutral-buffered formalin for 30 min. The
earts were fixed overnight. High-contrast film-based ra-
iographs (Model 43855A, Faxitron X-ray Corp., Lincoln-
hire, Illinois) were performed to locate and assess device
lacement.
EM ANALYSIS. Intact stented arterial segments were bi-
ected longitudinally to expose the lumen surface and
hotographed. One-half of the stent was processed for
EM with the opposite side reserved for immunostaining
nd confocal imaging. Specimens were rinsed in 0.1 mmol/l
odium phosphate buffer (pH 7.2  0.1) and then post-
xed in 1% osmium tetroxide for approximately 30 min.
pecimens were then dehydrated in a graded series of
thanol. After critical point drying, the tissue samples were
ounted and sputter-coated with gold. The specimens were
isualized using a Hitachi Model 3600N SEM (Tokyo,
apan). Low power photographs of 15 were taken of the
umen surface to estimate the degree of endothelialization of
he implant. Regions of interest were photographed at
ncremental magnifications of 50, 200, and 600.
omposites of serial en face SEM images acquired at low
ower (15) were digitally assembled to provide a complete
iew of the entire luminal stent surface. The images were
urther enlarged (200 magnification) allowing direct visu-
lization of ECs. The extent of endothelial surface coverage
bove and between stent struts (Fig. 1, right panels) was
raced and measured by morphometry software (IPLab, BD
ioscience Bioimaging, Rockville, Maryland) and reported
s percent endothelial coverage. In the overlapping stent
tudy, each stent combination underwent evaluation of the
verlapping zones as well as the nonoverlapping zone. An
verage of each stent segment in the nonoverlapping zones
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71as obtained from the sum of each specific stent type (SES
nd GS segments).
M ANALYSIS. CM was used to evaluate the presence of
ature ECs (presence of CD31/PECAM-1 positive cells).
xplanted vessels were stained for CD31/PECAM-1
MCA 1746, Serotec, Duesseldorf, Germany). TOTO-3
T3604, conjugated by fluoro642/660, Molecular Probes,
B Applied Biosystem, Invitrogen Corp., Carlsbad, Cali-
ornia) was used as counter-stain (concentrations: CD31/
ECAM-1  1:40, TOTO  1:100). Alexa Fluor 488
7 pigs (21 vesPHASE 1
7 pigs (21 ve
12 overlapped / 
SEM / CM
4 GS+GS
4 GS+SES
4 SES+SES
3
3
14 day3 days
7 i (12 l) 6 i (10 p gs  vesse
12 single (PECAM-1)
4 GS
4 SES with anti-CD34
 p gs  v
10 single (PE
4 GS
3 SES with a
S
4 SES 3 SES
SEM / CM SEM
PHA E 2 13 pigs (22 ve
Figure 1. Study Design Diagram
Phase 1 was conducted to demonstrate endothelialization rates and endotheli
metal stents [BMS]) and overlapped SES and GS. Phase 2 was conducted to de
re-endothelialization as compared with SES alone at both 3 and 14 days. All st
endothelialization) and confocal microscopy (CM) (platelet endothelial cell adh
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Figure 2. Effect of Sirolimus on EPC and HCAEC Proliferation at Different C
(A) Endothelial progenitor cell (EPC); and (B) human coronary artery endotheli
and HCAECs. However, a lower dose of sirolimus resulted in a signiﬁcant decrease inonkey anti-mouse (Invitrogen Corp., A21202, Carlsbad,
alifornia) was used as a secondary antibody for CD31/
ECAM-1 with concentration of 1:200. Specimens were
ounted on glass slides, and representative images were
cquired with a Zeiss Pascal confocal microscope. Low
ower images of the luminal surface were collected using a
0 objective to estimate the degree of expression of EC
arkers. Representative fields from the proximal, mid, and
istal ends were imaged for each stent with the observer
linded to treatment. The percentage of CD31-positive
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72ells was estimated in between and above stent struts at
roximal, overlapped site, and distal regions (10). Proximal
nd distal surface of the nonstented regions served as control
egions.
tatistical analysis. For the cell studies, the means of the
bsorbance readings were normalized to % of control (media
nly), and statistical analyses included a 1-way analysis of
ariance and post-hoc analyses with a Dunnett’s test. For
alculation of half maximum inhibitory concentration val-
es, a nonlinear regression analysis was performed, utilizing
sigmoidal dose response curve with the following equa-
ion: Y  Bottom  (Top  Bottom)/(1  10^[(Log IC50
X)·HillSlope]); where X is the logarithm of the drug
oncentration, Y is the response, and ^ is exponent (Graph-
ad Prism 5.0, San Diego, California).
For pre-clinical studies in the porcine model, data were
xpressed as a mean  SD. Statistical comparisons were
erformed using nonparametric test (Wilcoxon test for
groups and Kruskal-Wallis test for 3 or more groups). A
value of 0.05 was considered statistically significant.
esults
n vitro: sirolimus effect on endothelial cell proliferation. In
he in vitro cell culture studies, CD34 cell (EPC) prolif-
ration started to decrease (11.3% reduction at 1 nmol/l
ompared with the control group, p  0.05) at lower doses
Table 1. SEM Analysis From Phase 1: Single Stenting
Stent Type GS (n  3) BMS (n  3) SES (n  3) p Value
Endothelialization
Above struts 99 2 99 2 55 19* 0.048
Between 99 1 99 1 88 8* 0.048
*Significantly different from Genous stent (GS) and bare-metal stent (BMS).
SEM scanning electron microscopy; SES sirolimus-eluting stent(s).
Table 2. Endothelialization by SEM From Phase 1: Overlapping and Nonove
Overlapping Stent Zone
Stent Group (Proximal-Distal) Location Area Covered (%
GS–GS (n 4) Above struts 95 6
Between 95 5
GS–SES (n  4) Above struts 79 5
Between 89 3
SES–SES (n  4) Above struts 36 14
Between 74 10
p value above struts 0.007
p value between 0.009Abbreviations as in Table 1.f sirolimus compared with HCAEC (0% reduction at
nmol/l compared with the control group, p  NS). In the
CAECs, cell inhibition appeared to be affected signifi-
antly at levels above 10 m. In both groups, there was
ignificant inhibition of cell proliferation above 100 m. In
eneral, the log IC50 of sirolimus was higher for CD34

ells (5.14  0.03) than for HCAECs (4.80  0.05),
uggesting that EPC may be more sensitive to the effects of
irolimus than more mature HCAEC (Fig. 2).
n vivo studies: phases 1 and 2 studies in the porcine
oronary artery model. PHASE 1: ASSESSMENT OF SINGLE
NDOVERLAPPING STENTSWITH GS, SES, AND BMS. SINGLE
TENTS AT 14 DAYS (SEM). A total of 9 stents (3 GS, 3 SES,
nd 3 BMS) were analyzed. At 14 days, stent surface
ndothelialization evaluated by SEM showed a significantly
igher extent of endothelial coverage above struts in the GS
99 2%) and the BMS (99 2%) compared with the SES
55  19%, p  0.048) (Table 1).
VERLAPPING STENT AT 14 DAYS (SEM AND CM). At 14 days,
total of 12 overlap combinations were included in the
nalysis of stent endothelialization (4 GSGS, 4 GSSES,
nd 4 SESSES). SEM analysis of the overlapping zone
howed an enhanced rate of endothelial coverage above the
truts in the GSGS group (95  6%) and the GSSES
roup (79  5%) compared with the SESSES group
36  14%, p  0.007) (Table 2, Fig. 3). The nonoverlap-
ing segments from all 3 combinations showed higher
ndothelialization rates above the struts in the GS segments
98  3% in GSGS combination, 100  0% in GSSES
ombination) as compared with the SES segments (62 
3% in GSSES combination and 46 20% in SESSES
ombination, p  0.0003) (Table 2). CM analysis showed a
lightly greater expression of CD31/PECAM-1 above the
tent surface in the overlapping zone of GSGS group
56  13%) and GSSES group (38  33%) compared
ith the SESSES group (25  23%); however, the
ng
Nonoverlapping Stent Zone
Stent Segment Location Area Covered (%)
GS segments (n 8) Above struts 98 3
(in GS–GS) Between 99 4
GS segment (n  4) Above struts 100 0
(in GS–SES) Between 100 0
SES segment (n  4) Above struts 62 33
(in GS–SES) Between 88 7
SES segments (n  8) Above struts 46 20
(in SES–SES) Between 85 10
0.0003
0.0006rlappi
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73ifferences did not reach a statistical significance (p 0.27).
hese differences, though not significant, may have biolog-
cal relevance. In the nonoverlapping zones, CD31/
ECAM-1 expression was significantly greater in the GS
egments (74  28%) compared with the SES segments
40  36%, p  0.01).
HASE 2: EVALUATION OF STENT ENDOTHELIALIZATION
N THE SES, GS, AND SES-ANTI-CD34. EARLY ENDOTHELIAL-
ZATION AT 3 DAYS (SEM AND CM). A total of 12 stents (4
S, 4 SES, and 4 SES–anti-CD34 stents) were implanted
n 7 pigs and harvested at 3 days. GS showed the greatest
ndothelialization (76  8%) among groups, and there was
lso an increase in endothelial strut coverage in the SES–
nti-CD34 (36  26%) as compared with the SES group
7  3%) (p  0.01) (Table 3, Fig. 4A). Confocal
icroscopic analysis of the stent surface demonstrated
bundant expression of CD31/PECAM-1 over the surface
f the GS group whereas the SES–anti-CD34 and the SES
howed minimal expression (Table 3, Fig. 4B).
NDOTHELIAL RECOVERY AT 14 DAYS (SEM AND CM). A
otal of 10 stents (3 SES–anti-CD34 stents, 4 GS, and 3
ES) were implanted in 6 pigs and harvested at 14 days.
ndothelialization above stent struts was nearly completed
n the GS (98  2%) at 14 days, and was also increased in
he SES–anti-CD34 stent (78  3%) as compared with the
ES group (53  20% p  0.02) (Table 3, Figs. 4A and
GS + GS
GS + SES
SES + SES
Figure 3. Representative SEM Images From Phase 1 Study Involving Overla
Arrows point to the area of overlap and higher magniﬁcation of the overlap i
ization except for the overlapping site. Then least endothelialization is noted iC). Similarly, CD31/PECAM-1 expression was almostomplete in the GS group (96  7%) and also increased in
he SES–anti-CD34 stent group (72  8%) but remained
ow in the SES group (41  28%, p  0.03) (Table 3,
ig. 4B).
Stents
n on the left. GSGS overlapping stents showed near complete endothelial-
SESSEM overlap. Abbreviations as in Figure 1.
Table 3. SEM and CM Analysis From Phase 2: Single Stenting
Stent Type GS SES–Anti-CD34 SES p Value
Endothelialization (SEM)
3 days (n  4 each)
Above struts 76 8 36 26* 7 3*† 0.01
Between 86 5 78 3 61 9*† 0.009
14 days (n  4/3/3)
Above struts 98 2 82 8 53 20*† 0.02
Between 100 0 96 2 94 4* 0.03
PECAM-1 expression (CM)
3 days (n  4 each)
Above struts 59 25 1 2* 0 0* 0.009
Between 81 14 64 5* 50 8* 0.009
14 days (n  4/3/3)
Above struts 96 7 72 8 41 28* 0.03
Between 100 0 97 3 88 9* 0.03
*Significantly different from GS; †significantly different from SES with immobilized anti-CD34-
antibody (SES–anti-CD34).
CM  confocal microscopy; PECAM  platelet endothelial cell adhesion molecule; otherpping
s showabbreviations as in Table 1.
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74iscussion
e-endothelialization after stent implantation and vascular
njury is a critical step in the process of vascular healing. The
rigin of new endothelium may be from either the adjacent
ecruitment of ECs (1) or from blood-derived EPCs that
opulate the luminal surface of the stent (2). In the setting
f drug-eluting stent implantation, however, this pattern of
ascular healing is altered as there is nonselective inhibition
f all cell types (i.e., smooth muscle and ECs) involved in
he process of stent coverage (4,5). Therefore, a paradox
Figure 4. Endothelialization by SEM and CD-31 Expression in
SES–Anti-CD34 Stents and SES at 14 Days
(A) Endothelialization by SEM. (B) CD31/PECAM expression by confocal
microcopy harvested at 3 and 14 days. *Signiﬁcantly different vs. GS. (C)
Representative images from SEM and confocal microscopy, SES–anti-CD34
stent versus SES 14 days. Note, endothelial coverage in SES–anti-CD34 is
greater than that in SES by SEM. Also a greater CD31/PECAM-1 expression
(green channel) observed in SES–anti-CD34 stent as compared with SES
alone. Abbreviations as in Figure 1.n the development of drug-eluting stent technologies is rhat the beneficial effect of drug elution is overshadowed by
he nonselective inhibition of stent endothelialization (11–14).
n the present study we aimed to determine if antihuman-
D34 antibodies immobilized on the surface of a commer-
ially available SES could enhance the degree of stent endo-
helialization compared with the SES surface alone.
Previous experience with stents with immobilized anti-
uman CD34 antibody on the device surface (Genous
io-engineered R stent, OrbusNeich) has shown enhancing
tent endothelialization in vitro (6) as well as feasibility and
afety in clinical setting (7,8). The in vitro cell culture study
emonstrated that EPCs are more sensitive to the effects of
irolimus compared with mature human coronary artery
C. In fact, in our study, EPCs required a lower dose of
irolimus concentration to induce a similar level of cell
nhibition. In the same study (data not shown), the log
IC50) found for human coronary smooth muscle cell
nhibition was very similar to the concentration needed to
nhibit EPC proliferation to the same level (5.14  0.03 for
PC, 5.23  0.08 for human coronary smooth muscle cell,
nd 4.80  0.05 for HCAEC). Therefore, the biological
ndings of the antiproliferative effect of sirolimus on
mooth muscle cells are similar to the effects on ECs and
PCs (15–17). It is likely that by increasing EPC adhesion
n the surface of a drug-eluting stent, a greater vascular
ealing could be achieved while maintaining therapeutic
issue levels of the drug for smooth muscle cell inhibition.
In single stents, we demonstrated that endothelialization
ates were dramatically lower in the SES group compared
ith GS and BMS. Consistent with single stents, the
verlapping SES displayed a lower rate of EC coverage
specially at the midoverlap region. This finding may be of
linical relevance where overlapping stents showed signifi-
antly delayed arterial healing. Importantly, this delayed
e-endothelialization in SES was ameliorated partially by
verlapping with GS, thus suggesting that combination
herapy of antiproliferative drug and prohealing treatments
ould be combined. Our findings were further reinforced by
onfocal microscopic analysis, which revealed an increased
resence of mature ECs when assessed for PECAM-1
xpression in GSSES overlapping segments as compared
ith SESSES segments. There is a disparity between %
ndothelialization by SEM and % PECAM-1 positive (by
M analysis), which was consistent with our previous study
10). This may be related to the fact that ECs with poor
ntercellular junctions display a lack of PECAM-1 ex-
ression at endothelial margins, though these areas are
onsidered endothelialized by SEM. PECAM-1 is a
ransmembrane glycoprotein concentrated in broad areas
f cell-to-cell contact where homophilic interactions with
eighboring ECs occur (18,19). Therefore, a decrease of
ECAM-1 expression suggests an impaired endothelialecovery, maturity, and functionality.
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75In the subsequent phase 2 study, we successfully demon-
trated that anti-CD34 antibody application on the surface
f SES improved re-endothelialization as compared with
ES alone at both 3 and 14 days. Of note, the endotheli-
lization rates of the GS were approximately 2-fold greater
han the SES–anti-CD34 stent at 3 days. Endothelializa-
ion was almost completed by 14 days in the GS and
ncreased by 45% (up to 70%) in the SES–anti-CD34
tent. CM demonstrated that in the GS group most of the
ndothelium showed well-formed intercellular junction
ith CD31/PECAM-1 being expressed at 3 days in con-
rast to the minimal positive staining seen in the SES–anti-
D34 and in the SES groups. However, by 14 days, the
resence of mature endothelium was 80% in the SES–
nti-CD34 stent and 40% in the SES group, thus show-
ng that although endothelialization is delayed in the SES–
nti-CD34 stent at an early time point as compared with
he GS, at 14 days the SES–anti-CD34 stent shows
omparable endothelialization and its maturation relative to
S, which is significantly faster than the SES alone.
onclusions
irolimus inhibits EPC, SMC, and mature EC prolifera-
ion. However, our study demonstrates that it is feasible to
ombine antiproliferative therapies with technologies de-
igned to increase stent endothelialization, particularly
PC-capturing, with the objective of promoting vascular
ealing (20,21). Furthermore, anti-CD34 antibody surface
odification did enhance stent endothelialization when
pplied on SES. In conclusion, these studies demonstrated
hat antibody-mediated EPC capture can enhance EC
overage and maturation of ECs on drug-eluting stents and
ay provide a new therapeutic approach.
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